|
43 Companies |
|
40 Products |
|
40 Products |
|
30 Mechanisms of Action |
|
1 Trial |
|
293 News |
|
| «1234567» |
- Trial primary completion date: Single Incision Versus Standard Laparoscopic Splenectomy (clinicaltrials.gov) - Feb 5, 2015
P=N/A, N=30, Recruiting, Sponsor: Children's Mercy Hospital Kansas City
Trial primary completion date: Oct 2013 --> Oct 2016
- Zolinza (vorinostat) / Merck (MSD)
Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date: Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study (clinicaltrials.gov) - Jan 28, 2015
P4, N=0, Withdrawn, Sponsor: Boston University
Trial primary completion date: Oct 2013 --> Oct 2016 N=10 --> 0 | Initiation date: Feb 2013 --> Jan 2015 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2015 --> Jan 2015
- linerixibat (GSK2330672) / GSK
Trial primary completion date: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus (clinicaltrials.gov) - Jan 22, 2015
P1, N=40, Recruiting, Sponsor: GlaxoSmithKline
N=10 --> 0 | Initiation date: Feb 2013 --> Jan 2015 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2015 --> Jan 2015 Trial primary completion date: Dec 2014 --> Apr 2015
- ||||||| morphine sulphate / Generic mfg.
Trial completion, Trial primary completion date: Naloxone for the Treatment of Opioid-Induced Pruritus (clinicaltrials.gov) - Jan 20, 2015
P2/3, N=92, Completed, Sponsor: University of British Columbia
Trial primary completion date: Dec 2014 --> Apr 2015 Recruiting --> Completed | Trial primary completion date: Oct 2014 --> Apr 2013
- | Promacta (eltrombopag) / Novartis
Trial completion: Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects (clinicaltrials.gov) - Jan 20, 2015
P1, N=39, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed | Trial primary completion date: Oct 2014 --> Apr 2013 Not yet recruiting --> Completed
- ||| New P1 trial: Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis (clinicaltrials.gov) - Jan 9, 2015
P1, N=690, Active, not recruiting, Sponsor: Taro Pharmaceuticals USA
- dexamethasone / Generic mfg., prednisone / Generic mfg.
New P3 trial: EIS2002: Daily Prednisone Versus Pulsed Dexamethasone in Treatment-na (clinicaltrials.gov) - Jan 8, 2015
P3, N=26, Completed, Sponsor: University Hospital, Essen
- || tradipitant (VLY-686) / Vanda
Trial primary completion date: Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis (clinicaltrials.gov) - Jan 6, 2015
P2, N=68, Recruiting, Sponsor: Vanda Pharmaceuticals
Not yet recruiting --> Completed Trial primary completion date: Aug 2014 --> Mar 2015
- danazol oral / Generic mfg.
Trial primary completion date: Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP) (clinicaltrials.gov) - Dec 30, 2014
P2, N=25, Recruiting, Sponsor: Beth Israel Medical Center
Trial primary completion date: Aug 2014 --> Mar 2015 Trial primary completion date: Dec 2014 --> Dec 2015
- | otesaconazole (VT-1161) / Mycovia Pharma
Trial completion: A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate - Severe Interdigital Tinea Pedis (clinicaltrials.gov) - Dec 25, 2014
P2, N=50, Completed, Sponsor: Viamet Pharmaceuticals, Inc.
Trial primary completion date: Dec 2014 --> Dec 2015 Active, not recruiting --> Completed
- Trial completion, Enrollment change: Multiclear Treatment for Striae Distensae - A Pilot Study (clinicaltrials.gov) - Dec 17, 2014
P2, N=15, Completed, Sponsor: National University Hospital, Singapore
Active, not recruiting --> Completed Recruiting --> Completed | N=20 --> 15
- Clinical: FOX-TREG: Study of the Role of Regulator T Cells in the Pathophysiology of Childhood Henoch Schönlein Purpura (clinicaltrials.gov) - Dec 16, 2014
P=N/A, N=120, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire de Nīmes
- |||||| Tavalisse (fostamatinib) / Rigel
Enrollment open: A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Dec 10, 2014
P3, N=75, Recruiting, Sponsor: Rigel Pharmaceuticals
Recruiting --> Completed | N=20 --> 15 Not yet recruiting --> Recruiting
- |||| Promacta (eltrombopag) / Novartis
Trial primary completion date: EXTEND (Eltrombopag Extended Dosing Study) (clinicaltrials.gov) - Dec 7, 2014
P3, N=302, Active, not recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Trial primary completion date: Jul 2014 --> Dec 2014
- | methylprednisolone sodium succinate / Generic mfg.
Clinical: A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP. (clinicaltrials.gov) - Nov 20, 2014
P3, N=36, Recruiting, Sponsor: The Hospital for Sick Children
Trial primary completion date: Jul 2014 --> Dec 2014 Trial primary completion date: Dec 2014 --> Dec 2015
- ||||| Tavalisse (fostamatinib) / Rigel
Trial initiation date: A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Nov 17, 2014
P3, N=75, Not yet recruiting, Sponsor: Rigel Pharmaceuticals
Trial primary completion date: Dec 2014 --> Dec 2015 Initiation date: Jun 2014 --> Nov 2014
- lovastatin / Generic mfg.
Trial primary completion date: NeuSTART2: Neuroprotection With Statin Therapy for Acute Recovery Trial Phase 2 (clinicaltrials.gov) - Nov 12, 2014
P2, N=168, Recruiting, Sponsor: Mitchell S Elkind
Initiation date: Jun 2014 --> Nov 2014 Trial primary completion date: Mar 2014 --> Jun 2015
- | Promacta (eltrombopag) / Novartis
New P1 trial: Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects (clinicaltrials.gov) - Nov 3, 2014
P1, N=39, Not yet recruiting, Sponsor: GlaxoSmithKline
- |||| Promacta (eltrombopag) / Novartis
Trial completion: PETIT: Efficacy and Safety Study of Eltrombopag in Pediatric Patients With Thrombocytopenia From Chronic Idiopathic Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Oct 31, 2014
P2, N=82, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Mar 2014 --> Jun 2015 Active, not recruiting --> Completed
- || morphine sulphate / Generic mfg.
New P3 trial: Comparison of Epidural Oxycodone and Epidural Morphine (clinicaltrials.gov) - Oct 30, 2014
P3, N=100, Recruiting, Sponsor: KK Women's and Children's Hospital
- Trial completion, Enrollment change: TcBili: Transcutaneous Measurement of Jaundice in the Newborn (clinicaltrials.gov) - Oct 28, 2014
P=N/A, N=1000, Completed, Sponsor: Norwegian University of Science and Technology
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=1500 --> 1000
- Trial initiation date, Trial suspension, Trial primary completion date: Honey in Chronic Immune Thrombocytopenia (clinicaltrials.gov) - Oct 22, 2014
P2, N=30, Suspended, Sponsor: mamdouh abdulmaksoud abdulrhman
Active, not recruiting --> Completed | N=1500 --> 1000 Initiation date: Jan 2012 --> Oct 2014 | Not yet recruiting --> Suspended | Trial primary completion date: Jun 2012 --> Nov 2014
- ||||| Nplate (romiplostim) / Amgen, Kyowa Kirin
Enrollment closed, Trial primary completion date: Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients (clinicaltrials.gov) - Oct 20, 2014
P3, N=62, Active, not recruiting, Sponsor: Amgen
Initiation date: Jan 2012 --> Oct 2014 | Not yet recruiting --> Suspended | Trial primary completion date: Jun 2012 --> Nov 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Mar 2015
- |||| Privigen (human immune globulin intravenous 10%) / CSL Behring
Trial completion, Preclinical, Enrollment change, Trial primary completion date: A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - Oct 20, 2014
P4, N=57, Completed, Sponsor: CSL Behring
Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2015 --> Mar 2015 Recruiting --> Completed | N=150 --> 57 | Trial primary completion date: Sep 2015 --> Sep 2014
- Rituxan (rituximab) / Roche
Phase classification, Combination therapy: Rituximab and Prednisone as First-Line Therapy in Treating Patients With Immune Thrombocytopenic Purpura (clinicaltrials.gov) - Oct 17, 2014
P0, N=22, Completed, Sponsor: Mayo Clinic
Recruiting --> Completed | N=150 --> 57 | Trial primary completion date: Sep 2015 --> Sep 2014 Phase classification: P=N/A --> P0
- Trial completion, Enrollment change, Trial primary completion date: Treatment of Neonatal Jaundice With Filtered Sunlight Phototherapy: Safety and Efficacy in African Neonates (clinicaltrials.gov) - Oct 15, 2014
P1/2, N=1273, Completed, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Phase classification: P=N/A --> P0 Recruiting --> Completed | N=616 --> 1273 | Trial primary completion date: Nov 2014 --> Sep 2013
- BI 655064 / AbbVie, Boehringer Ingelheim
Trial primary completion date: Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP). (clinicaltrials.gov) - Oct 10, 2014
P1, N=10, Recruiting, Sponsor: Boehringer Ingelheim
Recruiting --> Completed | N=616 --> 1273 | Trial primary completion date: Nov 2014 --> Sep 2013 Trial primary completion date: Oct 2015 --> Feb 2016
- cetirizine oral / Generic mfg.
Enrollment open, Trial initiation date, Trial primary completion date: Study of Using Long Acting Antihistamine to Treat Opioid Induced Itching (clinicaltrials.gov) - Sep 28, 2014
P4, N=73, Recruiting, Sponsor: Virginia Commonwealth University
Trial primary completion date: Oct 2015 --> Feb 2016 Not yet recruiting --> Recruiting | Initiation date: Mar 2014 --> Sep 2014 | Trial primary completion date: Oct 2015 --> Oct 2016
- Promacta (eltrombopag) / Novartis
Trial primary completion date: Promacta Pregnancy Registry (clinicaltrials.gov) - Sep 19, 2014
P=N/A, N=1, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting | Initiation date: Mar 2014 --> Sep 2014 | Trial primary completion date: Oct 2015 --> Oct 2016 Trial primary completion date: Jan 2015 --> Jan 2016
- New P2 trial, Preclinical: KR: Evaluation of Preclinical Toxicity andTherapeutic Efficacy of Kandhaga Rasayanam in Padarthamarai (clinicaltrials.gov) - Sep 12, 2014
P2, N=50, Completed, Sponsor: National institute of Siddha
- ||||| Korsuva IV (difelikefalin IV) / Cara Therap, Maruishi Pharma, Vifor
New P2 trial: Safety and Pharmacokinetics of IV CR845 in Hemodialysis Patients, and Its Efficacy in Patients With Uremic Pruritus (clinicaltrials.gov) - Sep 4, 2014
P2, N=84, Recruiting, Sponsor: Cara Therapeutics, Inc.
- Enrollment closed: NATURAL KILLER CELLS IN IMMUNOLOGIC THROMBOCYTOPENIC PURpura of Adults (clinicaltrials.gov) - Aug 29, 2014
P=N/A, N=80, Active, not recruiting, Sponsor: Assistance Publique Hopitaux De Marseille
Trial primary completion date: Jan 2015 --> Jan 2016 Recruiting --> Active, not recruiting
- prednisone / Generic mfg., cyclosporin A microemulsion / Generic mfg., hydrocortisone / Generic mfg.
Trial primary completion date: Study of Cyclosporine or Corticosteroids as an Adjunct to Plasma Exchange in Thrombotic Thrombocytopenic Purpura (TTP) (clinicaltrials.gov) - Aug 15, 2014
P3, N=62, Recruiting, Sponsor: Ohio State University
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2015 --> Aug 2017
- ||||| blisibimod (A-623) / Anthera Pharma
Trial initiation date, Trial primary completion date: MONICA-SC: A Study to Evaluate the Efficacy, Safety and Tolerability of Blisibimod (A-623) Administration in Subjects With ITP (clinicaltrials.gov) - Aug 6, 2014
P2/3, N=60, Not yet recruiting, Sponsor: Anthera Pharmaceuticals
Trial primary completion date: Nov 2015 --> Aug 2017 Initiation date: Dec 2014 --> Dec 2015 | Trial primary completion date: Jun 2015 --> Jun 2016
- Nplate (romiplostim) / Amgen, Kyowa Kirin
Enrollment open: Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training (clinicaltrials.gov) - Aug 5, 2014
P=N/A, N=40, Recruiting, Sponsor: Amgen
Initiation date: Dec 2014 --> Dec 2015 | Trial primary completion date: Jun 2015 --> Jun 2016 Not yet recruiting --> Recruiting
- Enrollment open: Multiclear Treatment for Striae Distensae - A Pilot Study (clinicaltrials.gov) - Jul 30, 2014
P2, N=20, Recruiting, Sponsor: National University Hospital, Singapore
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Benlysta (belimumab) / GSK
Enrollment change, Trial withdrawal, Trial primary completion date: A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia. (clinicaltrials.gov) - Jul 24, 2014
P2, N=0, Withdrawn, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting N=48 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2013 --> Apr 2015
- Clinical: Educational Needs of Patients With Systemic Vasculitis (clinicaltrials.gov) - Jul 15, 2014
P=N/A, N=386, Completed, Sponsor: University of South Florida
- Clinical: Reproductive Health in Men and Women With Vasculitis (clinicaltrials.gov) - Jun 27, 2014
P=N/A, N=467, Completed, Sponsor: University of South Florida
- New P2 trial: Metal or Plastic Stents to Relieve Obstruction of Obstructive Jaundice Prior to Resection of Periampullary Tumors. (clinicaltrials.gov) - Jun 19, 2014
P2, N=50, Enrolling by invitation, Sponsor: Karolinska University Hospital
- Enrollment change: Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers (clinicaltrials.gov) - Jun 12, 2014
P=N/A, N=211, Completed, Sponsor: Seoul National University Hospital
N=48 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jul 2013 --> Apr 2015 N=149 --> 211
- Trial completion: Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers (clinicaltrials.gov) - Jun 12, 2014
P=N/A, N=211, Completed, Sponsor: Seoul National University Hospital
N=149 --> 211 Recruiting --> Completed
- |||| Nplate (romiplostim) / Amgen, Kyowa Kirin
Trial primary completion date: Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients (clinicaltrials.gov) - Jun 1, 2014
P3, N=60, Recruiting, Sponsor: Amgen
Recruiting --> Completed Trial primary completion date: Apr 2015 --> Oct 2015
- || Trial primary completion date: Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001) (clinicaltrials.gov) - May 28, 2014
P1, N=52, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Apr 2015 --> Oct 2015 Trial primary completion date: Sep 2014 --> Jan 2015
- | Trial completion date: Single Rising Dose Study of MK-8723 in Healthy Participants and Participants With Immune Thrombocytopenia Purpura (MK-8723-001) (clinicaltrials.gov) - May 28, 2014
P1, N=52, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Sep 2014 --> Jan 2015 Trial completion date: Sep 2014 --> Jan 2015
- ||||| Tavalisse (fostamatinib) / Rigel
Trial initiation date: A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - May 21, 2014
P3, N=75, Recruiting, Sponsor: Rigel Pharmaceuticals
Trial completion date: Sep 2014 --> Jan 2015 Initiation date: Apr 2014 --> May 2014
- |||||| Tavalisse (fostamatinib) / Rigel
Enrollment open: A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) - May 21, 2014
P3, N=75, Recruiting, Sponsor: Rigel Pharmaceuticals
Initiation date: Apr 2014 --> May 2014 Not yet recruiting --> Recruiting
- BI 655064 / AbbVie, Boehringer Ingelheim
Trial primary completion date: Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP). (clinicaltrials.gov) - May 18, 2014
P1, N=10, Recruiting, Sponsor: Boehringer Ingelheim
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2015 --> Oct 2015
- BI 655064 / AbbVie, Boehringer Ingelheim
Trial completion date: Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP). (clinicaltrials.gov) - May 18, 2014
P1, N=10, Recruiting, Sponsor: Boehringer Ingelheim
Trial primary completion date: Sep 2015 --> Oct 2015 Trial completion date: Sep 2015 --> Oct 2015
- | methylprednisolone sodium succinate / Generic mfg.
Clinical: A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP. (clinicaltrials.gov) - May 12, 2014
P3, N=36, Recruiting, Sponsor: The Hospital for Sick Children
Trial completion date: Sep 2015 --> Oct 2015 Trial primary completion date: Jan 2009 --> Dec 2014